Clinical Trial Update: Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating transfer of the CD40 ligand gene (AdcuCD40L) to patients with esophageal cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• AdcuCD40L

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Esophageal Neoplasms | Phase 1 | Status: WITHDRAWN